Introgen Therapeutics Gets $5 Million Milestone Payment From R-PR
Rhone-Poulenc Rorer has made a $5 million milestone payment to USgene-based cancer therapeutics firm Introgen Therapeutics. The milestone was triggered for continued progress in Introgen's p53 in vivo gene therapy program. The company is currently conducting several Phase I/II clinical trials, in collaboration with RPR Gencell, R-PR's gene therapy division. By the end of 1997, Introgen says it expects to have received at least $44 million of the potential $50 million under the collaboration deal signed with R-PR in October 1994.
Introgen chairman and chief executive David Nance says the firm has established "proof of principle in the ability to deliver and express normal p53 in tumors where it can exert a therapeutic effect and plans to conduct more extensive clinical trials .....with the goal of fast-track registration."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze